This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of CoQ10 Administration on Hemodialysis Patients

This study has been completed.
Information provided by:
University of Shizuoka Identifier:
First received: March 27, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted
The purpose of this study is to examine whether CoQ10 administration is effective as an antioxidant in hemodialysis patients.

Condition Intervention Phase
Chronic Renal Failure Hemodialysis Drug: Coenzyme Q10 (drug) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients

Resource links provided by NLM:

Further study details as provided by University of Shizuoka:

Primary Outcome Measures:
  • Oxidative protein concentration at 6 month
  • Antioxidant capacity at 6 month

Estimated Enrollment: 40
Study Start Date: March 2004
Estimated Study Completion Date: December 2004
Detailed Description:
Oxidative stress has been recognized as a potential risk factor for such complications as atherosclerosis in hemodialysis patients. This study investigates whether CoQ10 administration is effective for protecting oxidative stress in hemodialysis patients. The subjects were recruited from day-time hemodialysis patients in Iwata City Hospital. 100 mg CoQ10 was administered every HD for 6 months. Several oxidative and antioxidative markers were measured in plasma at pre, 1, 3, 6 months and after washout.

Ages Eligible for Study:   up to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hemodialysis for at least 6 months

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00307996

Iwata City Hospital
Iwata, Shizuoka, Japan, 438-8550
Sponsors and Collaborators
University of Shizuoka
Study Chair: Hiromichi Kumagai, MD University of Shizuoka
  More Information Identifier: NCT00307996     History of Changes
Other Study ID Numbers: CT2006001
Study First Received: March 27, 2006
Last Updated: March 27, 2006

Keywords provided by University of Shizuoka:
oxidative marker

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Coenzyme Q10
Growth Substances
Physiological Effects of Drugs
Vitamins processed this record on August 21, 2017